Facebook-f Twitter Linkedin Youtube
Facebook-f Twitter Linkedin Youtube

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach (part 1 of 2)

Program Overview

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Click for Part 2

0.25 CE Credit(s)
Expires: April 21, 2023

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Educational Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Faculty

Dulai

Parambir S. Dulai, MD

Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine Northwestern University
Evanston, IL

Lukin_Dana@2x

Dana Lukin, MD, PhD

Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Provider Statement

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Supporter Statement

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Featured RMEI CE Activities

Copyright © 2022. RMEI Medical Education, LLC. All rights reserved​

Privacy | Terms of Use

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources